Opinion|Videos|October 18, 2024
Use of Long-term NMOSD Data in Clinical Practice
Author(s)Sean Pittock, MD
Key Takeaways
- Long-term data aids in optimizing treatment plans by offering insights into efficacy, safety, and patient outcomes over time.
- Staying updated with research findings is essential for integrating long-term data into clinical practice to enhance patient care.
Sean Pittock, MD, discusses how he utilizes long-term data in his clinical practice for treating neuromyelitis optica spectrum disorder and offers advice for physicians on incorporating these insights into patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How are you utilizing these long-term data in your clinical practice, and what advice do you have for physicians?
Advertisement
Related to this article
The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.
Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.
IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.
uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.
Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study
2
Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development
3
AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS
4
NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease
5